Abstract

**Background:** Rapid growth should occur among children with severe malnutrition (SM) when medically and nutritionally treated. Systemic inflammation (SI) is associated with death among children with SM and is negatively associated with linear growth. However, the relationship between SI and weight gain during therapeutic feeding following acute illness is unknown. We hypothesised that growth in the first 60 days post-hospital discharge is associated with SI among children with SM.

**Methods:** We conducted secondary analysis of data from HIV-uninfected children with SM (n=98) who survived and were not readmitted to hospital during one year of follow up. We examined the relationship between changes in absolute deficits in weight and mid-upper-arm circumference (MUAC) from enrolment at stabilisation to 60 days later and untargeted plasma proteome, targeted cytokines/chemokines, leptin, and soluble CD14 (sCD14) using multivariate regularized linear regression.

**Results:** The mean change in absolute deficit in weight and MUAC was -0.50kg (standard deviation; SD±0.69) and -1.20cm (SD±0.89), respectively, from enrolment to 60 days later. During the same period, mean weight and MUAC gain was 3.3g/kg/day (SD±2.4) and 0.22mm/day (SD±0.2), respectively. Enrolment inflammatory cytokines interleukin 17 alpha (IL17α), interleukin 2 (IL2), and serum amyloid P (SAP) were negatively associated with weight and MUAC gain. Lipopolysaccharide binding protein (LBP) and complement component Open Peer Review

**Reviewer Status**

<table>
<thead>
<tr>
<th>Invited Reviewers</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>version 2</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>(revision)</td>
<td>16 Mar 2021</td>
<td></td>
</tr>
<tr>
<td>version 1</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>22 Oct 2020</td>
<td>report</td>
<td>report</td>
</tr>
</tbody>
</table>

1. **Sana Syed**, University of Virginia, Charlottesville, USA

2. **Lubaina Ehsan**, University of Virginia, Charlottesville, USA

2. **Keith P. West**, Johns Hopkins University Bloomberg School of Public Health, Baltimore, USA

Any reports and responses or comments on the article can be found at the end of the article.
2 were negatively associated with weight gain only. Leptin was positively associated with weight gain. sCD14, beta-2 microglobulin (β2M), and macrophage inflammatory protein 1 beta (MIP1β) were negatively associated with MUAC gain only.

**Conclusions:** Early post-hospital discharge weight and MUAC gain were rapid and comparable to children with uncomplicated SM treated with similar diet in the community. Higher concentrations of SI markers were associated with less weight and MUAC gain, suggesting inflammation negatively impacts recovery from wasting. This finding warrants further research on the role of inflammation on growth among children with SM.

**Keywords**
severe malnutrition, child growth, weight, mid-upper arm circumference, anthropometric deficit, inflammation, cytokines, proteome
Introduction
In 2018, approximately 50.5 million children under five years old globally were wasted, of which 16 million were severely wasted\(^1\). Wasting is associated with elevated mortality, mainly due to susceptibility to infectious diseases\(^2\-^4\). Current guidelines recommend that children with severe wasting or oedematous malnutrition who are acutely ill (complicated severe malnutrition; CSM) are initially medically treated and nutritionally stabilised as inpatients. Once stabilised, they are treated with high protein and energy feeds in the form of ready-to-use therapeutic foods (RUTF) to achieve catch-up weight gain as outpatients\(^6\-^7\).

Severely malnourished children admitted to hospital with acute illness may suffer relapse, readmission, or death after discharge from hospital\(^8\-^13\) and are at risk of impaired neurocognitive development\(^14\-^18\). Children may return to household settings of poverty, social disadvantage, environmental contamination, and inadequate access to healthcare\(^19\-^25\). Enhanced prevention of recurrent illnesses over longer periods following hospitalisation and improved dietary quality have been suggested as opportunities to improve growth\(^26\-^29\).

RUTF was designed to fulfil 100% of the nutritional needs of children recovering from SM and may theoretically enable weight gain of up to 20 g/kg/day\(^30\). The weight gain velocity is usually high at the start of the therapeutic feeding, then decreases and plateaux\(^31\-^34\). Weight gain may be affected by comorbidities such as HIV or other chronic infections but may also be related to intestinal or systemic inflammation (SI), leading to reduced appetite, nutrient malabsorption, and metabolic changes\(^35\-^37\).

SI is demonstrable at the time of hospital discharge in children with SM\(^38\). However, it is not known how long inflammation persists or what its effects are on weight gain. SI is known to suppress linear growth indirectly through the growth hormone/insulin growth factor 1 (GH/IGF1) axis, and directly through effects on long bone growth plate chondrocytes\(^39\)\-^41\). Besides linear growth, SI may affect gain in adipose and muscle through promoting a persistent catabolic state and dysregulation of the usual hormonal and metabolic processes of these tissues\(^42\-^44\).

Both nutrient scarcity and acute illness are associated with a catabolic state\(^45\) with negative effects on the body’s storage organs, mainly adipose and muscle. During refeeding of children with SM, significant systemic metabolic shifts are observed that relate to the muscle, liver, and the adipose tissue among others\(^46\-^48\). We therefore hypothesised that among children with SM treated in hospital for an acute illness, weight gain is associated with SI. The objective of this study was to investigate the relationship between plasma proteomic and cytokine profiles and weight gain among HIV negative children with SM in the first 60 days of post-hospital discharge following medical stabilisation.

Methods
Ethics approval and consent to participate
The trial was approved by the Kenya National Ethical Review Committee (SSC 1562) and the Oxford Tropical Research Ethics Committee (OXTREC reference 18-09). Secondary analyses were approved by the Scientific and Ethical Review Unit (SERU 2782). The trial was registered at clinicaltrials.gov (NCT00934492, 8th July 2009). Informed consent for data and sample collection, storage, and future research had been obtained from mothers or guardians of study participants during recruitment to the trial.

Study design and patient recruitment
This was a secondary analysis of data from a nested case control study\(^38\) within a clinical trial (NCT00934492) that tested the efficacy of daily co-trimoxazole prophylaxis in reducing post-discharge mortality among HIV-uninfected children aged 2–59 months hospitalised with CSM in two urban (Mombasa and Nairobi) and two rural (Kilifi and Malindi) hospitals in Kenya\(^4\). Children were included in the trial if they had mid-upper-arm circumference (MUAC) <11.5cm if aged ≥6 months and <11.0cm if aged 2–5 months or had oedematous malnutrition; and had a negative HIV rapid-antibody test; and had completed the stabilisation phase of treatment as defined in WHO guidelines. Children were enrolled just prior to discharge from hospital. Discharge was according to WHO guidelines, based on clinical recovery rather than achieving an anthropometric threshold. At hospital discharge, nutritional counselling was given to caregivers, along with RUTF dosed as per WHO and Kenyan guidelines, and families were actively referred to community-based management of acute malnutrition (CMAM) centres located either at the hospital or in community facilities to continue therapeutic feeding. Children were actively followed up for 12 months, monthly in the first six months, and at months eight, 10 and 12. Study participants were traced at home if they defaulted and loss to follow-up was minimal (≤5%). The trial intervention had no overall effect on reducing mortality or hospital readmission.

Participants selected for this study had served as controls in a previous case control study\(^49\). Briefly, the case to control ratio in the case control study was 1:1 and there were 121 cases (deaths) that were analysed that had sufficient samples from among 147 deaths that had occurred within the first 60 days of enrolment into the trial. Control children (n=120) had been randomly selected without replacement amongst 1119 children who survived and were not readmitted to hospital during 12 months of trial follow up using the ‘sample’ command in STATA (version 15.1, TX, USA). For this study, 12 children who were oedematous at enrolment and another 10 children that lacked anthropometry data at month 2 to month 6 were excluded from the analysis. We therefore analysed data for 98 children in which plasma proteomic and cytokine measurements had been done on enrolment samples.
Data sources and measurements
During enrolment and at follow-up, child and caregiver demographic characteristics, immunisation status, clinical examination, admission diagnoses, chronic conditions, and anthropometry (weight, height or length, MUAC) were collected. Weight was measured with the use of an electronic scale (Seca 825), length or height with the use of an infantometer (Seca 416) or stadiometer (Seca 215), and MUAC with the use of insertion tape (TALC)⁴. The WHO (2006) growth references were used to calculate Z scores.

Proteomics and cytokines measurement in plasma
Untargeted plasma proteomics were measured by liquid chromatography tandem mass spectrometry and targeted cytokines, chemokines, leptin and soluble CD14 by Luminex and ELISA as previously described⁹.

Bioinformatics and statistical analysis
The primary and secondary outcomes were the change in absolute deficits in weight (DWAD) and MUAC (DMAD), respectively, from enrolment to 60 days. Absolute deficit was defined as the median value for age according to WHO growth charts minus the child’s measured value. Absolute deficit was used rather than Z scores for weight-for-age (WAZ) or weight-for-height (WHZ) because changes in standard deviation across age or length makes them less appropriate for measuring changes over time among children of different ages⁴⁹. Exposure variables were the plasma proteome, leptin, sCD14 and a panel of targeted cytokines that are markers of inflammation and immune activation. Regression models were adjusted for age, sex, randomisation and site, whilst regression to the mean was addressed by including enrolment anthropometric values in the regression models. We hypothesised that proteins measured at baseline would have their strongest effect on early growth (within 60 days) than at later time points. We conducted the analysis in the R statistical software version 3.6.2⁶ and performed a multivariate regularized linear regression analysis using an elastic net (EN) model implemented using the “glmnet” package. This package fits a penalized linear model via penalized maximum likelihood. EN is a penalized regression approach and integrates two regularized approaches, ridge regression and LASSO (Least Absolute Shrinkage and Selection Operator), wherein the contribution of each of these models to the final EN model is controlled by the α parameter⁷⁻⁸. The EN penalty is controlled by α and bridges the gap between LASSO (α=1, the default) and ridge (α=0). The tuning parameter lambda (λ) that controls the overall strength of the penalty was determined using five-fold cross validation. The strong penalization imposed by LASSO draws non-predictive coefficients to zero, thereby eliminating proteins from the models, whereas ridge regression addresses potential multi-collinearity problems in high-dimensional data⁹⁻¹⁰. Variables such as age, sex, randomisation arm and site were treated as prior confounders and were not subjected to penalization by imposing a penalty factor of 0. All other variables had a penalty factor of 1 and were subjected to penalization. We used the ‘caret’ package in R to automatically select the best tuning parameters alpha and lambda by testing a range of possible alpha and lambda values. The best alpha and lambda values are those values that minimize the cross-validation error. EN model generation was performed separately for each growth outcome: change in Weight Absolute Deficit (DWAD) (primary outcome) and change in MUAC Absolute Deficit (DMAD) (secondary outcome), with protein profiles, cytokines, and enrolment anthropometric variables as predictors. The subset of variables assigned non-zero coefficients were considered optimal and were retained in each of the final multi-variable models. Finally, bootstrapping was used to evaluate the robustness of selected proteins at 1000 iterations using the ‘BootValidation’ package in R on the elastic net model with the optimized regularization value (α=0.5) and analytes selected by the model for more than 60%⁴⁹ of times were considered as important protein features.

Results
Characteristics of study participants
Study participants’ characteristics are shown in Table 1. At enrolment, 89% of the children were over six months of age⁶⁰. Children were also severely stunted at enrolment and this was unchanged after 60 days despite large MUAC and weight gains with nutritional rehabilitation (all P<0.01). Haemoglobin, total white blood cell count, and lymphocyte count increased, while neutrophil and platelet counts decreased between enrolment and 60 days (P<0.01) (Table 1).

Children have higher growth rates during the first two months post-discharge
Overall, mean weight gain for 60 days was 3.3g (SD: ±2.4) per kilogram per day. The mean MUAC and length/height gains for 60 days were 0.22mm (SD: ±0.2) per day and 0.34mm (SD: ±0.25) per day, respectively (Table 2). Changes in weight and MUAC during enrolment to 60 days were larger than during days 61–120 and days 121–180 (p<0.01) (Table 2). Differences in height between enrolment to 60 days were not significantly different from days 61–120 or days 121–180 (both p>0.1) (Table 2).

The mean change in absolute deficits in weight (DWAD) and MUAC (DMAD) were -0.5kg (SD: ±0.69) and -1.20cm (SD: ±0.89), respectively, and these were higher in the first 60 days when compared to the periods between 61–120 days or 121–180 days (P<0.001). There was a significant difference in the change in height deficit (DHAD) between the first 60 days and 61–120 days (P<0.03) but not at 121–180 days (P=0.08).

Inflammatory cytokines and proteins are negatively associated with change in growth deficit at two months
Change in weight absolute deficit (DWAD). In the multivariate elastic net (EN) regularized regression model adjusted for confounders, inflammatory cytokines interleukin 17 alpha (IL17a) and interleukin 2 (IL2), complement component 2 (C2), lipopolysaccharide binding protein (LBP), amyloid P component, serum (APCS or SAP), among others were negatively associated with DWAD in the first 60 days (Figure 1a). Further, our analysis showed that the adipokine leptin was positively associated with DWAD (Figure 1a).
Change in MUAC absolute deficit (DMAD). Inflammatory cytokines IL17a, IL2, and MIP1B were negatively associated with DMAD in the first 60 days (Figure 1b). Angiotensinogen (AGT), the precursor of all angiotensin peptides; soluble CD14 (sCD14), a co-receptor for the detection of bacterial lipopolysaccharide (LPS); beta-2 microglobulin (β2M), a component of MHC class I molecules which are present on all nucleated cells; and SAP, were negatively associated with DMAD (Figure 1b).

Only IL17a, IL2, and SAP were associated with both DWAD and DMAD (Figure 1c) even though these two anthropometric measurements were significantly correlated as shown in Figure 1d. Both models were significantly associated to
their respective growth outcome, accounting for just over half of the variability in growth (DWAD $r^2$=0.57 and DMAD $r^2$=0.51, Table 3).

Bootstrap analysis. After 1000 bootstrap iterations, only IL17a was identified in >60% of the DWAD model repetitions (Figure 1e) indicating that this was the most robust feature associated with weight gain. Using similar iterations during bootstrap validation for the DMAD model, no features were extracted at the 60% threshold and the most frequently selected features were IL17a (55%), B2M (55%), AGT (49%), SAP (48%), and sCD14 (48%) as shown (Figure 1f).

Discussion

We investigated the relationship between inflammatory cytokines and plasma proteomic profiles and change in anthropometric deficits during the early post-hospital discharge period as this is the period most likely to be related to biological factors measured at discharge and when catch up in weight deficit is at its greatest. The mean weight gain rate of 3.3 g/kg/day observed was comparable to that reported for uncomplicated SM treated with a similar diet in the community. However, there were significant reductions in absolute deficits of weight and MUAC. Although markers of SI were negatively associated with growth in the early post-hospital discharge period, substantial growth did occur in the presence of markers of inflammation. It is likely that the large metabolic shifts observed during refeeding with energy dense therapeutic feeds favours tissue accretion even in the presence of SI. It is notable that despite absolute increases in height, there was no significant reduction in absolute deficit of height, indicating that catch-up growth mainly occurs in the adipose and muscle and not long bones. No comparable data on inflammatory markers are published from children with uncomplicated SM. However, lack of an acute illness means it is plausible that there is less systemic inflammation. Overall, our results indicate that growth is influenced by inflammation status.

Inflammatory cytokines IL17a, IL2, and MIP1B and inflammatory proteins sCD14, LBP, SAP, and β2M were negatively associated with weight gain and MUAC. IL17a is produced by T-helper 17 (Th17) cells that play a role in host defence against extracellular pathogens through recruitment of neutrophils and macrophages to infected tissues. IL17a is involved in tissue inflammation by release of other pro-inflammatory cytokines and inducing neutrophil chemotaxis and is implicated in obesity and adipogenesis. In humans, increased expression of IL17a has been reported in inflammatory bowel disease. sCD14 is secreted by monocytes and macrophages commonly in response to LPS translocation, while LBP is plasma protein that binds to the lipid A moiety of bacterial LPS. β2M is released by activated T and B lymphocytes and plasma β2M has been described as a predictive biomarker for many vascular inflammatory diseases. SAP is an acute phase protein and belongs to the pentraxins family of proteins that also includes C-reactive protein, which exhibit calcium-dependent binding to several different molecules and pathogens. Children included in this study were judged by trained clinicians as clinically stabilised following an acute illness and induction of these inflammatory cytokines and proteins likely results from induction by microbial molecules. Several of these cytokines are elevated in patients with inflammatory bowel disease and may reflect the presence of environmental enteric dysfunction, which is common in low- and middle-income countries, that is associated with linear growth failure.

Our results show that leptin was positively associated with growth. Leptin levels increase with accretion of adipose tissue mass and therefore leptin levels are related to body weight. Leptin was first recognized for its prominent action on the hypothalamus to control food intake, energy expenditure and, hence, body weight. It is also involved in immune homeostasis by differentially regulating T cells, enhancing Th1 and suppressing Th2 cytokine production, and reversing starvation-induced immunosuppression. Among Ugandan children hospitalised with SM, nutritional stabilisation and weight gain was associated with significant increases in leptin levels. However, it is worth noting that leptin levels which were

Table 2. Bimonthly anthropometric growth indices of children during the first 180 days post-hospital discharge.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Enrolment-60 days</th>
<th>61days–120 days</th>
<th>p value</th>
<th>121days–180days</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Δ Weight (kg), mean ±SD</td>
<td>1.08±0.70</td>
<td>0.58±0.50</td>
<td>&lt;0.001</td>
<td>0.40±0.44</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Δ MUAC (cm), mean ±SD</td>
<td>1.33±0.89</td>
<td>0.51±0.65</td>
<td>&lt;0.001</td>
<td>0.27±0.58</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Δ Height (cm), mean ±SD</td>
<td>2.07±1.55</td>
<td>2.23±1.30</td>
<td>0.33</td>
<td>1.97±1.19</td>
<td>0.55</td>
</tr>
<tr>
<td>DWAD (kg), mean ±SD</td>
<td>-0.50±0.69</td>
<td>-0.10±0.48</td>
<td>&lt;0.001</td>
<td>-0.05±0.43</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>DMAD (cm), mean ±SD</td>
<td>-1.20±0.89</td>
<td>-0.39±0.66</td>
<td>&lt;0.001</td>
<td>-0.18±0.58</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>DHAD (cm), mean ±SD</td>
<td>-0.53±1.40</td>
<td>-0.08±1.23</td>
<td>0.03</td>
<td>-0.18±1.12</td>
<td>0.08</td>
</tr>
</tbody>
</table>

*p value was derived from a paired t test between 0–60days and 61–120days or 121–180days values. Δ = change, mo. = month, MUAC = mid-upper-arm circumference, DWAD = change in absolute deficits in weight, DMAD = change in absolute deficits in MUAC, DHAD = change in absolute deficits in height.
measured at hospital discharge may still be low among children with SM.

Proinflammatory signalling in the adipocyte is required for proper adipose tissue remodelling and expansion84 and recent studies suggest that low grade inflammation may play a positive role in weight gain in both children85 and adults86. In a population-based longitudinal study in the Brazilian Amazon among children ≤10 years, low-grade inflammation (c-reactive protein <1 mg/L at baseline) was predictive of annual gain in BMI-for-age during follow-up85. During refeeding, severely malnourished children may adopt an obesogenic metabolic phenotype, where tissue accretion occurs in the presence of inflammation and reflecting restoration of adipose tissue lost due to malnutrition87. However, inflammation increases energy expenditure and in animal studies focusing on increasing production, SI is attributed to inefficient nutrient utilization efficiency which translated to low gain in weight, implying that in that context, persistent inflammation negatively affects growth88–91.
The limitations of this study include the relatively small sample size, the lack of serial measurements of inflammatory markers and body composition, and that children with oedema were excluded from the analysis. This study was carried out at four sites in Kenya only. Every child was tested for HIV, enabling us to exclude its effect. Important nutritional factors, hormones and growth factors, and metabolites which would have contributed further to the understanding of the relationship between SI and growth were not determined. Molecules such as LPS that would explain elevated SI were not determined and were beyond the scope of this study. The untargeted proteomics and targeted Luminex and ELISA approaches used in this study provided a broad array of protein molecules from which to identify molecules associated with early post-hospital discharge growth.

Conclusions
Among children with SM, early post-hospital discharge catch-up growth in weight and MUAC is rapid. Higher concentrations of markers of SI were associated with less weight and MUAC gain, suggesting inflammation negatively impacts recovery from wasting. Our results indicate that growth is influenced by inflammation status and warrants further research on the role of inflammation on growth among children with SM.

Data availability
Underlying data
Specific variables such as personal identifiers and the longitude and latitude co-ordinates of study participants were removed to enhance participant anonymisation and can be accessed following application to our Data Governance Committee at dgc@kemri-wellcome.org. The replication data and analysis scripts for this manuscript are available from the Harvard Dataverse. Harvard Dataverse: Replication data for: Systemic Inflammation is Negatively Associated with Early Post Discharge Growth following Acute Illness among Severely Malnourished Children- a Pilot Study. https://doi.org/10.7910/DVN/5DKLV10.

This project contains the following underlying data:
• (a) Njunge_CTX_15092020.dta
• (b) Njunge_CTX_15092020.csv

Both (a) and (b) files contain similar information. The files contain anthropometric measurements at the time of hospital discharge and during follow up months 1, 2, 3, 4, 5, 6, 8, 10, and 12. A full blood count at enrolment, 2, 6, and 12 months. The two files were generated using STATA/IC (version 15.1; StataCorp, College Station, TX, USA)
• Njunge_Inflammation_Codebook.pdf: It contains a list of all the variables in the two datasets and their description.

Extended data

This project contains the following extended data:
• Njunge_EN_Glmnet_bootValidation.R: This analysis script uses Njunge_CTX_15092020.csv to perform multivariate regularized linear regression analysis using an elastic net (EN) model implemented using the “glmnet” package and fits a generalized linear model via penalized maximum likelihood. It generates an EN model separately for each growth outcome (change in Weight Absolute Deficit(DWAD) (primary outcome) and change in MUAC Absolute Deficit (DMAD) (secondary outcome), with protein profiles, cytokines, and enrolment anthropometric variables as predictors. The subset of variables assigned non-zero coefficients are retained in each of the final multi-variable models. It then performs Bootstrapping to evaluate the robustness of selected proteins at 1000 iterations using the ‘BooValidation’ package. The analysis was performed using R Studio (R version 3.6.2 (2019-12-12))
• Njunge_Stata_Do.do: This analysis script uses Njunge_CTX_15092020.dta to generate the summary participants characteristics at enrolment and at 2 months and calculate the changes in anthropometry
• NjungeJM_Inflammation_Readme.txt: It contains description of the related study, file contents, data license and usage instructions.

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

Acknowledgements
We thank the study participants, their families, the four study hospitals, and the clinical staff at the KEMRI-Wellcome Trust Programme.

This paper is published with the permission of the Director of the Kenya Medical Research Institute.


Open Peer Review

Current Peer Review Status:  

Version 1

Reviewer Report 09 December 2020

https://doi.org/10.21956/wellcomeopenres.17953.r41116

© 2020 West K. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Keith P. West
Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA

This study examines the potential attenuating influence of inflammation at time of discharge on subsequent linear and ponderal growth of young children initially hospitalized for severe complicated, non-HIV-related malnutrition. Inflammation at discharge was assessed by a combined assessment of cytokines (IL-2, IL17a and SAP) and relative abundance of plasma protein biomarkers, including those whose expression covaries with phases of the inflammatory response. The study is an important follow-up from a previous case-control study (Njunge et al Sci Reports 2019) but also because it adds new insights amidst a sparsity of studies harnessing the potential of plasma proteomics to reveal metabolic alterations and pathways that may be affecting recovery-related (catch-up) child growth following severe malnutrition.

Comments:

The methods would benefit from slightly more essential study details that can render this paper independent of a previous paper (Njunge et al., Sci Reports 2019) as I found myself needing to return to that publication to better understand aspects of study design: please clarify when children were phlebotomized (presumably just prior to discharge that constitute enrolment samples), which is also equivalent to baseline.

Notwithstanding important details provided about the analytical methods, thresholds at which associations between DMAD and DWAD and protein relative abundance/cytokine concentrations are considered chance-adjusted, statistically significant are not specified. Is there a p- or q-value considered to be SS, and how were family-wise error probabilities from multiple comparisons managed? P-values for EN models for DWAD and DMAD are given in Table 3 but its not clear what these are testing or how derived.

Children were followed monthly through 6 mo and bi-monthly thereafter to 12 months. Given the measurements are available through 1-year post discharge, and partly reported as 60-day increments to 6 months of age in Table 2, the rationale for restricting evaluation of biomarker-growth deficit recovery to the 1st 60 days of follow-up, as opposed to longer, would benefit from
clearer argument. It would be easier to follow if all data were restricted to a 60-day period for this paper, which aligns with the survival findings reported in Njunge et al 2019\(^1\). That said, reporting associations between discharge inflammation status and growth over longer intervals would be an important contribution, as little is known about extended influences of inflammation and longer term growth in undernourished populations. One population cohort-based plasma proteomics study in Nepal has shown head size at birth (Lee SE et al Sci Reports 2018\(^2\)) and attained HAZ and WAZ at 6-8 years of age (Lee SE et al J Nutr 2017\(^3\)), to be associated with the relative abundance of a wide array of plasma proteins, including S100 calprotectins (A9 and A12 isomers, respectively), assessed at 6-8 years. The few such studies that exist suggest persistent (long term), bidirectional associations between child growth and metabolic pathways, as expressed through the plasma proteome, observations that pique interest to explore protein biomarker associations with extended growth endpoints, in this paper or a subsequent treatise.

To the extent time points are maintained, can the authors clarify if children were measured at exactly 60, 120 and 180 days post-enrollment? If not, how were growth intervals standardized to 60-day periods?

DHAD data are summarized in Table 2. Why was it not also a primary outcome?

Table 1: In the 1\(^{\text{st}}\) row, it would be informative to have a summary [median (IQR)] of ages of children at 60 days (removing “at enrolment” in the row label).

Table 3: The title is long and difficult to understand. Mention is made of correlation, but R\(^2\) is reported. Please shorten and articulate specifics in the footnotes, including the exposure protein variables in each model (assuming these are the proteins reported in Figure 1 and b?).

Figure 1: Please clarify the x-axis label in a and b as regression coefficient and in the legend, specify measurement unit for each. Findings from Figures 1e and 1f, presenting Inclusion Rates associated with DWAD and DMAD, are presently not mentioned in the Results.

Discussion

Three-quarters down the 1\(^{\text{st}}\) paragraph, noting the height deficit did not show evidence of recovery, could this be placing too high an expectation on long bone growth recovery commensurate with regaining soft tissue accretion within only 60 days?

Few typos:
Figure 1: Within the parentheses (d and f) should be (e and f);
In discussion – LBP is a plasma protein that binds...

References

Is the work clearly and accurately presented and does it cite the current literature? Yes

Is the study design appropriate and is the work technically sound? Yes

Are sufficient details of methods and analysis provided to allow replication by others? Partly

If applicable, is the statistical analysis and its interpretation appropriate? I cannot comment. A qualified statistician is required.

Are all the source data underlying the results available to ensure full reproducibility? Yes

Are the conclusions drawn adequately supported by the results? Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Nutritional epidemiology, applied proteomics, nutrition interventions, child growth, maternal nutrition.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 05 Mar 2021


Reviewer 1
Sana Syed, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, School of Medicine, University of Virginia, Charlottesville, VA, USA.
Lubaina Ehsan, University of Virginia, Charlottesville, VA, USA

Approved With Reservations
The manuscript submitted by Dr. Njunge and colleagues aims to investigate the association of systemic inflammation among early post-discharge children who are severely malnourished and have had an acute illness. Overall, this manuscript presents results that would be of interest to the community of scientists and clinicians concerned with this problem, major strengths of their work are:

- Well-written and coherent manuscript which clearly outlines the work that was done.
Strong statistical analysis of not only the weight/MUAC gain but also the absolute deficits in these measurements.

A discussion that outlines each significant result clearly with extensive literature being referenced.

The assessment of potential markers for growth being associated with inflammation which can pave the way for revised standards of anthropometric measurement among children within the same cohort.

However, there are a few issues in this manuscript that prevent us from recommending that this manuscript be indexed in its current state:

Overall

There is a mismatch between the introduction and the discussion. While the introduction mentions RUTF and GH/IGF1 axis, we also suggest adding the background behind the assessment of the relationship of plasma proteomic and cytokine profiles with growth. The discussion then excellently discussed the individual results for cytokines and other markers although, the background for these measurements being part of the introduction will make the foundation of why this work was done even more strong.

- Studies detailing the relationship between plasma proteomics and cytokine profiles on catch-up growth after an acute illness are very limited among undernourished children. We have added additional citations on linear growth. “In Nepal, birth size was inversely associated with low-grade, chronic inflammation during pregnancy as indicated by serum AGP and serum CRP. Further, head size at birth among Nepalese and attained z scores for height (HAZ) and weight-for-age (WAZ) at 6-8 years of age were associated with a wide array of plasma proteins, including S100 calprotectin subunits, assessed at 6-8 years. In community settings, SI is elevated in 17-34% children in LMIC (C-reactive protein >5mg/L or α1-antichymotrypsin >0.6g/L) and is associated with reduced linear growth.” However the literature is quite limited.

- The proteomics and cytokines measurements in plasma were measured using liquid chromatography tandem mass spectrometry and targeted cytokines, chemokines, leptin and soluble CD14 by Luminex and ELISA; however, cytokines are known to be variable and fluctuate in different physiological locations and environments, which is a limitation of the study. We would suggest the authors describe how they overcame this limitation.

We thank the reviewers for pointing out this limitation which we highlight in our study. We have added a statement in the main text about other unmeasured factors causing fluctuations in cytokine levels “we were unable to control for other factors that may influence cytokine levels”. Further, we lacked serial measurements of inflammatory markers. However, it has been shown that “in high income settings, survivors of sepsis have elevated markers of SI for up to 1 year and retain an increased mortality risk. After sepsis, systemic levels of C-reactive protein and soluble programmed death ligand 1 (a marker of immunosuppression) are elevated for up to 1 year in patients while IL6 and IL10 persists for several months in human and experimental models.” These data implicate SI in both short and longer-term growth outcomes post-discharge. We also agree with Reviewer 2 who points out that “reporting associations between discharge inflammation status and growth over longer intervals would be an important
contribution, as little is known about extended influences of inflammation and long-term growth in undernourished populations”.

Methods

- It is mentioned that the data was from a nested case control study within a clinical trial (NCT00934492) that tested the efficacy of daily co-trimoxazole prophylaxis. However, there was no comment found on the potential effect of co-trimoxazole prophylaxis as a confounder on the results for systematic inflammation. We suggest that a short explanation is added, whether in the main manuscript or supplemental material.

This was conducted and is indicated under the bioinformatics and statistics section of the manuscript. We adjusted for randomisation in the regression models to account for the potential effect of co-trimoxazole prophylaxis.

- The authors have used a 60-day cut-off post-discharge – was there a particular reason for selecting this and not any earlier/later time-point and any literature supporting assessment of growth at 60 days post-discharge?

We selected the 60-day post-discharge period because it’s when catch up in weight deficit was at its greatest and allows for short term convalescence. We also wished to retain the time-period at 60 days post-discharge as was the original design of the case-control mortality analysis\textsuperscript{17}. This is also the period most likely to be related to biological factors measured at discharge unlike the later time-points. Following the reviewers’ suggestions on the lack of data regarding extended influences of inflammation and longer-term growth in undernourished populations, we have conducted further analysis with growth deficits (weight, MUAC, and height) at 1 year and presented these results in the main text. We believe that this analysis on longer-term impact on growth is a valuable contribution to the field where the data is quite limited. Future analysis utilising other cohorts including the Childhood Acute Illness and Nutrition (CHAIN) Network Cohort in Kenya, Uganda, Malawi, Burkina Faso, Bangladesh and Pakistan that is examining mortality, readmission and growth among acutely ill children below 2 years\textsuperscript{18} will focus on longer time periods post-discharge. This was a pilot study and there is no literature to the best of our knowledge that guides assessment of growth at 60 days post-discharge. However, most community-based feeding studies have assessed growth between 1 and 6 months\textsuperscript{19-26}.

- We suggested clarifying how ‘absolute deficit’ was calculated. Absolute deficit was defined as the median value for age according to WHO growth charts minus the child’s measured value. We have added text to indicate that “It was calculated as the difference between the measured weight, height, or MUAC and the median age- and sex-specific value obtained from the WHO 2006 growth standards\textsuperscript{27-29}.”

Results

- Was there a difference noted for patients that were born prematurely or underweight since the eventual weight gain may have been due to regression to the mean? Any analysis that was done after excluding these patients?
Regression to the mean was addressed by including enrolment anthropometric values in the regression models. Except for one child, all children born premature were also underweight. The model outcomes did not change when we included the underweight variable in the model.

**Discussion**

○ A few comments are mentioned under the ‘overall’ heading. Any future directions for the current work?

○ Yes. “Future work should investigate effects over a longer time period post-discharge and compare with community participants/children without acute illness to establish community norms.” We have added this to the main text.

○ We also briefly suggest adding strengths of the study, although not necessary. Strengths included robust and standardised data collection within a clinical trial, follow-up for one year and very low loss to follow-up. This has been added on the main text.

Reviewer 2.  
Keith P. West, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA

**Approved With Reservations**

This study examines the potential attenuating influence of inflammation at time of discharge on subsequent linear and ponderal growth of young children initially hospitalized for severe complicated, non-HIV-related malnutrition. Inflammation at discharge was assessed by a combined assessment of cytokines (IL-2, IL17a and SAP) and relative abundance of plasma protein biomarkers, including those whose expression covaries with phases of the inflammatory response. The study is an important follow-up from a previous case-control study (Njunge et al Sci Reports 2019) but also because it adds new insights amidst a sparsity of studies harnessing the potential of plasma proteomics to reveal metabolic alterations and pathways that may be affecting recovery-related (catch-up) child growth following severe malnutrition.

**Comments:**

The methods would benefit from slightly more essential study details that can render this paper independent of a previous paper (Njunge et al., Sci Reports 2019) as I found myself needing to return to that publication to better understand aspects of study design: please clarify when children were phlebotomized (presumably just prior to discharge that constitute enrolment samples), which is also equivalent to baseline. We have adjusted the text to indicate that “Samples were collected from study participants prior to initiation of the investigational product: co-trimoxazole or placebo at discharge and constitute enrolment samples”.

Notwithstanding important details provided about the analytical methods, thresholds at which associations between DMAD and DWAD and protein relative abundance/cytokine concentrations are considered chance-adjusted, statistically
significant are not specified. Is there a p- or q-value considered to be SS, and how were family-wise error probabilities from multiple comparisons managed? P-values for EN models for DWAD and DMAD are given in Table 3 but its not clear what these are testing or how derived.

We did not infer associations between DMAD or DWAD with individual proteins. Instead, we directly performed a penalised multivariate analysis to model the association between all proteins and growth outcomes. Hence, only 2 multivariate models were made, resulting to the p-values reported in Table 3. Adjustment for multiple comparison is not typically used for these types of models and the elastic net method utilised aggressively penalised redundant and non-predictive protein features. The p-values for the EN models in Table 3 are the association between the actual DWAD/DMAD to the predicted DWAD/DMAD of the model. Therefore, the r value therefore represents the variance explained by the model, in which case our models captured 51% and 57% of the variance for DWAD and DMAD at month two, respectively.

Children were followed monthly through 6 mo and bi-monthly thereafter to 12 months. Given the measurements are available through 1-year post discharge, and partly reported as 60-day increments to 6 months of age in Table 2, the rationale for restricting evaluation of biomarker-growth deficit recovery to the 1st 60 days of follow-up, as opposed to longer, would benefit from clearer argument. It would be easier to follow if all data were restricted to a 60-day period for this paper, which aligns with the survival findings reported in Njunge et al 2019. That said, reporting associations between discharge inflammation status and growth over longer intervals would be an important contribution, as little is known about extended influences of inflammation and longer term growth in undernourished populations. One population cohort-based plasma proteomics study in Nepal has shown head size at birth (Lee SE et al Sci Reports 2018) and attained HAZ and WAZ at 6-8 years of age (Lee SE et al J Nutr 2017), to be associated with the relative abundance of a wide array of plasma proteins, including S100 calprotectins (A9 and A12 isomers, respectively), assessed at 6-8 years. The few such studies that exist suggest persistent (long term), bidirectional associations between child growth and metabolic pathways, as expressed through the plasma proteome, observations that pique interest to explore protein biomarker associations with extended growth endpoints, in this paper or a subsequent treatise.

We thank both reviewers for questioning the rationale for restricting evaluation of biomarker-growth deficit recovery to the 1st 60 days of follow-up, as opposed to longer. We have addressed this under reviewer 1 comment 2 in the methods section. We agree that reporting associations between discharge inflammation status and growth over longer intervals would be an important contribution, as little is known about extended influences of inflammation and longer-term growth in undernourished populations. We have therefore conducted further analysis with changes in growth deficits (weight, MUAC, and height) during one-year from enrolment, presented the results in the main text and discussed the findings. An interesting and strong association between Glutathione peroxidase 3 and one-year weight and MUAC deficit changes emerged. To extend this work, our next step is a planned detailed longitudinal analysis of the relationship between systemic inflammation and growth outcomes post-discharge among acutely ill children right across the nutritional spectrum using data and samples from a large recently completed cohort study in Africa and Asia.
To the extent time points are maintained, can the authors clarify if children were measured at exactly 60, 120 and 180 days post-enrollment? If not, how were growth intervals standardized to 60-day periods?
The mean number of days from enrolment to month two was 61.7 days (SD; 1.98), median [IQR] was 61 [61-63] days. The mean (SD) and median [IQR] number of days between months 2 – 4 and months 4 – 6 were: 61.5 (3.40); 61 [60-63] and 61.5 (6.41); 61 [59-63] respectively. Calculations on growth velocity were based on the difference between the measured values at enrolment and month two divided by the difference in the actual number of days between enrolment and the month two visit and subsequent visits.

DHAD data are summarized in Table 2. Why was it not also a primary outcome?
Various studies including ours\(^30\) have shown that children initially gain weight before height therefore we did not expect major differences in height gain in the first 60 days. When wasting and stunting co-exist in the same child, it has been observed that, whereas rapid catch-up in tissue growth commences as soon as treatment is initiated, the peak velocity for catch-up in linear growth occurs 1 to 3 months later\(^31\). This delay coincides with the time taken by children to attain a weight that is appropriate for their length\(^31\). The early post discharge period (within 2 months) is normally accompanied by high gains in weight compared to later time points. We also selected weight gain as primary analysis since the original trial design used severe wasting (mid-upper-arm circumference (MUAC) <11.5cm if aged ≥6 months and <11.0cm if aged 2–5 months or had oedematous malnutrition) as an enrolment criteria and not severe stunting\(^32\). We have however included changes in height in the new one-year analysis.

Table 1: In the 1\(^{st}\) row, it would be informative to have a summary [median (IQR)] of ages of children at 60 days (removing “at enrolment” in the row label). This has been edited and the median [IQR] of ages of children at 60 days included.

Table 3: The title is long and difficult to understand. Mention is made of correlation, but R\(^2\) is reported. Please shorten and articulate specifics in the footnotes, including the exposure protein variables in each model (assuming these are the proteins reported in Figure 1 and b?).
The title has been changed to read “Elastic Net regression model optimal alpha parameters and performance of proteins associated with change in growth deficits within 60 days”. We have also changed R\(^2\) to r. We have added a footnote that reads “Optimal alpha parameter and correlation coefficients for the EN model enumerating the correlation between DWAD and DMAD at two months and exposure protein variables (untargeted plasma proteome, and targeted cytokine/chemokines, leptin, sCD14, and CRP) extracted by the multivariate regularized models.”

Figure 1: Please clarify the x-axis label in a and b as regression coefficient and in the legend, specify measurement unit for each. Findings from Figures 1e and 1f, presenting Inclusion Rates associated with DWAD and DMAD, are presently not mentioned in the Results.
The x-axis label in Figure 1a and 1b now reads regression coefficient. Legend has been adjusted to read “Untargeted liquid chromatography tandem mass spectrometry plasma proteins, and targeted cytokines/chemokines, Leptin, sCD14, and CRP associated with
DWAD (a) and DMAD (b) in multivariate elastic net (EN) regularized linear regression models at two months. Log normalised protein values were used in the analysis and regression models were adjusted for age, randomisation arm, sex, respective enrolment growth deficits, and site."

The findings from Figure 1e and 1f are discussed under the subheading "Bootstrap analysis. After 1000 bootstrap iterations, only IL17a was identified in >60% of the DWAD model repetitions (Figure 1e) indicating that this was the most robust feature associated with weight gain. Using similar iterations during bootstrap validation for the DMAD model, no features were extracted at the 60% threshold and the most frequently selected features were IL17a (55%), B2M (55%), AGT (49%), SAP (48%), and sCD14 (48%) as shown (Figure 1f)."

Discussion

Three-quarters down the 1st paragraph, noting the height deficit did not show evidence of recovery, could this be placing too high an expectation on long bone growth recovery commensurate with regaining soft tissue accretion within only 60 days?

Our group and others have observed that during rehabilitation of severely malnourished children who were both wasted and stunted, weight gain is rapid and appetite is high until when such a child attain a weight appropriate for their length height/length gain.

Few typos:
Figure 1: Within the parentheses (d and f) should be (e and f); This has now been corrected as suggested.

In discussion – LBP is a plasma protein that binds... This has now been corrected as suggested.

References


Sana Syed
Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, School of Medicine, University of Virginia, Charlottesville, VA, USA

Lubaina Ehsan
University of Virginia, Charlottesville, VA, USA

The manuscript submitted by Dr. Njunge and colleagues aims to investigate the association of systemic inflammation among early post-discharge children who are severely malnourished and have had an acute illness. Overall, this manuscript presents results that would be of interest to the community of scientists and clinicians concerned with this problem, major strengths of their work are:

○ Well-written and coherent manuscript which clearly outlines the work that was done.
○ Strong statistical analysis of not only the weight/MUAC gain but also the absolute deficits in these measurements.
○ A discussion that outlines each significant result clearly with extensive literature being referenced.
○ The assessment of potential markers for growth being associated with inflammation which can pave the way for revised standards of anthropometric measurement among children within the same cohort.

However, there are a few issues in this manuscript that prevent us from recommending that this manuscript be indexed in its current state:

Overall
○ There is a mismatch between the introduction and the discussion. While the introduction mentions RUTF and GH/IGF1 axis, we also suggest adding the background behind the assessment of the relationship of plasma proteomic and cytokine profiles with growth. The discussion then excellently discussed the individual results for cytokines and other markers although, the background for these measurements being part of the introduction will make the foundation of why this work was done even more strong.

○ The proteomics and cytokines measurements in plasma were measured using liquid chromatography tandem mass spectrometry and targeted cytokines, chemokines, leptin and soluble CD14 by Luminex and ELISA; however, cytokines are known to be variable and fluctuate in different physiological locations and environments, which is a limitation of the
study. We would suggest the authors describe how they overcame this limitation.

**Methods**

- It is mentioned that the data was from a nested case control study within a clinical trial (NCT00934492) that tested the efficacy of daily co-trimoxazole prophylaxis. However, there was no comment found on the potential effect of co-trimoxazole prophylaxis as a confounder on the results for systematic inflammation. We suggest that a short explanation is added, whether in the main manuscript or supplemental material.

- The authors have used a 60 day cut-off post-discharge – was there a particular reason for selecting this and not any earlier/later time-point and any literature supporting assessment of growth at 60 days post-discharge?

- We suggested clarifying how ‘absolute deficit’ was calculated.

**Results**

- Was there a difference noted for patients that were born prematurely or underweight since the eventual weight gain may have been due to regression to the mean? Any analysis that was done after excluding these patients?

**Discussion**

- A few comments are mentioned under the ‘overall’ heading.
- Any future directions for the current work?
- We also briefly suggest adding strengths of the study, although not necessary.

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**

Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**

Yes

**Are all the source data underlying the results available to ensure full reproducibility?**

Partly

**Are the conclusions drawn adequately supported by the results?**

Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Gastroenterology, Nutrition, Data Science

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have
significant reservations, as outlined above.

Author Response 05 Mar 2021


Reviewer 1
Sana Syed, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, School of Medicine, University of Virginia, Charlottesville, VA, USA.
Lubaina Ehsan, University of Virginia, Charlottesville, VA, USA

Approved With Reservations
The manuscript submitted by Dr. Njunge and colleagues aims to investigate the association of systemic inflammation among early post-discharge children who are severely malnourished and have had an acute illness. Overall, this manuscript presents results that would be of interest to the community of scientists and clinicians concerned with this problem, major strengths of their work are:

- Well-written and coherent manuscript which clearly outlines the work that was done.
- Strong statistical analysis of not only the weight/MUAC gain but also the absolute deficits in these measurements.
- A discussion that outlines each significant result clearly with extensive literature being referenced.
- The assessment of potential markers for growth being associated with inflammation which can pave the way for revised standards of anthropometric measurement among children within the same cohort.

However, there are a few issues in this manuscript that prevent us from recommending that this manuscript be indexed in its current state:

Overall
There is a mismatch between the introduction and the discussion. While the introduction mentions RUTF and GH/IGF1 axis, we also suggest adding the background behind the assessment of the relationship of plasma proteomic and cytokine profiles with growth. The discussion then excellently discussed the individual results for cytokines and other markers although, the background for these measurements being part of the introduction will make the foundation of why this work was done even more strong.

- Studies detailing the relationship between plasma proteomics and cytokine profiles on catch-up growth after an acute illness are very limited among undernourished children. We have added additional citations on linear growth. “In Nepal, birth size was inversely associated with low-grade, chronic inflammation during pregnancy as indicated by serum AGP1,2. Further, head size at birth among Nepalese3 and attained z scores for height (HAZ) and weight-for-age (WAZ) at 6-8 years of age4 were associated with a wide array of plasma proteins, including S100 calprotectin subunits, assessed at 6-8 years. In community settings, SI is elevated in 17-34% children in LMIC5 (C-reactive protein >5mg/L or a1-antichymotrypsin >0.6g/L) and is associated with reduced linear growth6-10.” However the literature is quite limited11.
The proteomics and cytokines measurements in plasma were measured using liquid chromatography tandem mass spectrometry and targeted cytokines, chemokines, leptin and soluble CD14 by Luminex and ELISA; however, cytokines are known to be variable and fluctuate in different physiological locations and environments, which is a limitation of the study. We would suggest the authors describe how they overcame this limitation.

We thank the reviewers for pointing out this limitation which we highlight in our study. We have added a statement in the main text about other unmeasured factors causing fluctuations in cytokine levels “we were unable to control for other factors that may influence cytokine levels”. Further, we lacked serial measurements of inflammatory markers. However, it has been shown that “in high income settings, survivors of sepsis have elevated markers of SI for up to 1 year and retain an increased mortality risk. After sepsis, systemic levels of C-reactive protein and soluble programmed death ligand 1 (a marker of immunosuppression) are elevated for up to 1 year in patients while IL6 and IL10 persists for several months in human and experimental models.” These data implicate SI in both short and longer-term growth outcomes post-discharge. We also agree with Reviewer 2 who points out that “reporting associations between discharge inflammation status and growth over longer intervals would be an important contribution, as little is known about extended influences of inflammation and longer-term growth in undernourished populations”.

Methods

- It is mentioned that the data was from a nested case control study within a clinical trial (NCT00934492) that tested the efficacy of daily co-trimoxazole prophylaxis. However, there was no comment found on the potential effect of co-trimoxazole prophylaxis as a confounder on the results for systematic inflammation. We suggest that a short explanation is added, whether in the main manuscript or supplemental material.

This was conducted and is indicated under the bioinformatics and statistics section of the manuscript. We adjusted for randomisation in the regression models to account for the potential effect of co-trimoxazole prophylaxis.

- The authors have used a 60-day cut-off post-discharge – was there a particular reason for selecting this and not any earlier/later time-point and any literature supporting assessment of growth at 60 days post-discharge?

We selected the 60-day post-discharge period because it’s when catch up in weight deficit was at its greatest and allows for short term convalescence. We also wished to retain the time-period at 60 days post-discharge as was the original design of the case-control mortality analysis. This is also the period most likely to be related to biological factors measured at discharge unlike the later time-points. Following the reviewers’ suggestions on the lack of data regarding extended influences of inflammation and longer-term growth in undernourished populations, we have conducted further analysis with growth deficits (weight, MUAC, and height) at 1 year and presented these results in the main text. We believe that this analysis on longer-
term impact on growth is a valuable contribution to the field where the data is quite limited. Future analysis utilising other cohorts including the Childhood Acute Illness and Nutrition (CHAIN) Network Cohort in Kenya, Uganda, Malawi, Burkina Faso, Bangladesh and Pakistan that is examining mortality, readmission and growth among acutely ill children below 2 years will focus on longer time periods post-discharge. This was a pilot study and there is no literature to the best of our knowledge that guides assessment of growth at 60 days post-discharge. However, most community-based feeding studies have assessed growth between 1 and 6 months.

- **We suggested clarifying how ‘absolute deficit’ was calculated.** Absolute deficit was defined as the median value for age according to WHO growth charts minus the child’s measured value. We have added text to indicate that “It was calculated as the difference between the measured weight, height, or MUAC and the median age- and sex-specific value obtained from the WHO 2006 growth standards.”

**Results**

- **Was there a difference noted for patients that were born prematurely or underweight since the eventual weight gain may have been due to regression to the mean? Any analysis that was done after excluding these patients?** Regression to the mean was addressed by including enrolment anthropometric values in the regression models. Except for one child, all children born premature were also underweight. The model outcomes did not change when we included the underweight variable in the model.

**Discussion**

- **A few comments are mentioned under the ‘overall’ heading. Any future directions for the current work?**
  - Yes. “Future work should investigate effects over a longer time period post-discharge and compare with community participants/children without acute illness to establish community norms.” We have added this to the main text.

- **We also briefly suggest adding strengths of the study, although not necessary.** Strengths included robust and standardised data collection within a clinical trial, follow-up for one year and very low loss to follow-up. This has been added on the main text.

**Reviewer 2.**

Keith P. West, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA

**Approved With Reservations**

This study examines the potential attenuating influence of inflammation at time of discharge on subsequent linear and ponderal growth of young children initially hospitalized for severe complicated, non-HIV-related malnutrition. Inflammation at discharge was assessed by a combined assessment of cytokines (IL-2, IL17a and SAP) and relative abundance of plasma protein biomarkers, including those whose expression covaries with phases of the inflammatory response. The study is an important follow-up from a previous case-control study (Njunge et al Sci Reports 2019).
but also because it adds new insights amidst a sparsity of studies harnessing the potential of plasma proteomics to reveal metabolic alterations and pathways that may be affecting recovery-related (catch-up) child growth following severe malnutrition.

Comments:

The methods would benefit from slightly more essential study details that can render this paper independent of a previous paper (Njunge et al., Sci Reports 2019) as I found myself needing to return to that publication to better understand aspects of study design: please clarify when children were phlebotomized (presumably just prior to discharge that constitute enrolment samples), which is also equivalent to baseline. We have adjusted the text to indicate that "Samples were collected from study participants prior to initiation of the investigational product: co-trimoxazole or placebo at discharge and constitute enrolment samples”.

Notwithstanding important details provided about the analytical methods, thresholds at which associations between DMAD and DWAD and protein relative abundance/cytokine concentrations are considered chance-adjusted, statistically significant are not specified. Is there a p- or q-value considered to be SS, and how were family-wise error probabilities from multiple comparisons managed? P-values for EN models for DWAD and DMAD are given in Table 3 but its not clear what these are testing or how derived.

We did not infer associations between DMAD or DWAD with individual proteins. Instead, we directly performed a penalised multivariate analysis to model the association between all proteins and growth outcomes. Hence, only 2 multivariate models were made, resulting to the p-values reported in Table 3. Adjustment for multiple comparison is not typically used for these types of models and the elastic net method utilised aggressively penalised redundant and non-predictive protein features. The p-values for the EN models in Table 3 are the association between the actual DWAD/DMAD to the predicted DWAD/DMAD of the model. Therefore, the r value therefore represents the variance explained by the model, in which case our models captured 51% and 57% of the variance for DWAD and DMAD at month two, respectively.

Children were followed monthly through 6 mo and bi-monthly thereafter to 12 months. Given the measurements are available through 1-year post discharge, and partly reported as 60-day increments to 6 months of age in Table 2, the rationale for restricting evaluation of biomarker-growth deficit recovery to the 1st 60 days of follow-up, as opposed to longer, would benefit from clearer argument. It would be easier to follow if all data were restricted to a 60-day period for this paper, which aligns with the survival findings reported in Njunge et al 2019. That said, reporting associations between discharge inflammation status and growth over longer intervals would be an important contribution, as little is known about extended influences of inflammation and longer term growth in undernourished populations. One population cohort-based plasma proteomics study in Nepal has shown head size at birth (Lee SE et al Sci Reports 2018) and attained HAZ and WAZ at 6-8 years of age (Lee SE et al J Nutr 2017), to be associated with the relative abundance of a wide array of plasma
proteins, including S100 calprotectins (A9 and A12 isomers, respectively), assessed at 6-8 years. The few such studies that exist suggest persistent (long term), bidirectional associations between child growth and metabolic pathways, as expressed through the plasma proteome, observations that pique interest to explore protein biomarker associations with extended growth endpoints, in this paper or a subsequent treatise.

We thank both reviewers for questioning the rationale for restricting evaluation of biomarker-growth deficit recovery to the 1\textsuperscript{st} 60 days of follow-up, as opposed to longer. We have addressed this under reviewer 1 comment 2 in the methods section. We agree that reporting associations between discharge inflammation status and growth over longer intervals would be an important contribution, as little is known about extended influences of inflammation and longer-term growth in undernourished populations. We have therefore conducted further analysis with changes in growth deficits (weight, MUAC, and height) during one-year from enrolment, presented the results in the main text and discussed the findings. An interesting and strong association between Glutathione peroxidase 3 and one-year weight and MUAC deficit changes emerged. To extend this work, our next step is a planned detailed longitudinal analysis of the relationship between systemic inflammation and growth outcomes post-discharge among acutely ill children right across the nutritional spectrum using data and samples from a large recently completed cohort study in Africa and Asia\textsuperscript{18}.

To the extent time points are maintained, can the authors clarify if children were measured at exactly 60, 120 and 180 days post-enrollment? If not, how were growth intervals standardized to 60-day periods?

The mean number of days from enrolment to month two was 61.7 days (SD; 1.98), median [IQR] was 61 [61-63] days. The mean (SD) and median [IQR] number of days between months 2 – 4 and months 4 – 6 were: 61.5 (3.40); 61 [60-63] and 61.5 (6.41); 61 [59-63] respectively. Calculations on growth velocity were based on the difference between the measured values at enrolment and month two divided by the difference in the actual number of days between enrolment and the month two visit and subsequent visits.

DHAD data are summarized in Table 2. Why was it not also a primary outcome?

Various studies including ours\textsuperscript{30} have shown that children initially gain weight before height therefore we did not expect major differences in height gain in the first 60 days. When wasting and stunting co-exist in the same child, it has been observed that, whereas rapid catch-up in tissue growth commences as soon as treatment is initiated, the peak velocity for catch-up in linear growth occurs 1 to 3 months later\textsuperscript{31}. This delay coincides with the time taken by children to attain a weight that is appropriate for their length\textsuperscript{31}. The early post discharge period (within 2 months) is normally accompanied by high gains in weight compared to later time points. We also selected weight gain as primary analysis since the original trial design used severe wasting (mid-upper-arm circumference (MUAC) <11.5cm if aged \geq 6 months and <11.0cm if aged 2–5 months or had oedematous malnutrition) as an enrolment criteria and not severe stunting\textsuperscript{32}. We have however included changes in height in the new one-year analysis.

Table 1: In the 1\textsuperscript{st} row, it would be informative to have a summary [median (IQR)] of ages of children at 60 days (removing “at enrolment” in the row label). This has been edited and the median [IQR] of ages of children at 60 days included.
Table 3: The title is long and difficult to understand. Mention is made of correlation, but $R^2$ is reported. Please shorten and articulate specifics in the footnotes, including the exposure protein variables in each model (assuming these are the proteins reported in Figure 1 and b?).

The title has been changed to read “Elastic Net regression model optimal alpha parameters and performance of proteins associated with change in growth deficits within 60 days”. We have also changed $R^2$ to $r$. We have added a footnote that reads “Optimal alpha parameter and correlation coefficients for the EN model enumerating the correlation between DWAD and DMAD at two months and exposure protein variables (untargeted plasma proteome, and targeted cytokine/chemokines, leptin, sCD14, and CRP) extracted by the multivariate regularized models.”

Figure 1: Please clarify the x-axis label in a and b as regression coefficient and in the legend, specify measurement unit for each. Findings from Figures 1e and 1f, presenting Inclusion Rates associated with DWAD and DMAD, are presently not mentioned in the Results.

The x-axis label in Figure 1a and 1b now reads regression coefficient. Legend has been adjusted to read “Untargeted liquid chromatography tandem mass spectrometry plasma proteins, and targeted cytokines/chemokines, Leptin, sCD14, and CRP associated with DWAD (a) and DMAD (b) in multivariate elastic net (EN) regularized linear regression models at two months. Log normalised protein values were used in the analysis and regression models were adjusted for age, randomisation arm, sex, respective enrolment growth deficits, and site.”

The findings from Figure 1e and 1f are discussed under the subheading “Bootstrap analysis. After 1000 bootstrap iterations, only IL17a was identified in >60% of the DWAD model repetitions (Figure 1e) indicating that this was the most robust feature associated with weight gain. Using similar iterations during bootstrap validation for the DMAD model, no features were extracted at the 60% threshold and the most frequently selected features were IL17a (55%), B2M (55%), AGT (49%), SAP (48%), and sCD14 (48%) as shown (Figure 1f).”

Discussion
Three-quarters down the 1st paragraph, noting the height deficit did not show evidence of recovery, could this be placing too high an expectation on long bone growth recovery commensurate with regaining soft tissue accretion within only 60 days?

Our group and others have observed that during rehabilitation of severely malnourished children who were both wasted and stunted, weight gain is rapid and appetite is high until when such a child attain a weight appropriate for their length/height/length gain.

Few typos:
Figure 1: Within the parentheses (d and f) should be (e and f);
This has now been corrected as suggested.

In discussion – LBP is a plasma protein that binds... This has now been corrected as suggested.
References

12 Yende, S. et al. Inflammatory markers at hospital discharge predict subsequent...


27 Leroy, J. L., Ruel, M., Habicht, J.-P. & Frongillo, E. A. Linear Growth Deficit Continues to Accumulate beyond the First 1000 Days in Low- and Middle-Income Countries: Global


**Competing Interests:** None